CytomX Therapeutics Inc (DE:6C1)
FRANKFURT:6C1
Holding DE:6C1?
Track your performance easily

CytomX Therapeutics (6C1) Financial Statements

2 Followers

CytomX Therapeutics Financial Overview

CytomX Therapeutics's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; CytomX Therapeutics is scheduled to report earnings on November 7, 2024, and the estimated EPS forecast is €-0.16. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 25.11M$ 41.46M$ 26.61M$ 26.38M$ 24.72M
Gross Profit$ 25.11M$ 41.46M$ 26.61M$ 26.38M$ 24.72M
EBIT$ -6.48M$ 11.66M$ -606.00K$ 5.82M$ -1.09M
EBITDA$ -4.16M$ 12.12M$ -120.00K$ 4.37M$ -2.20M
Net Income Common Stockholders$ -6.53M$ 13.79M$ 837.00K$ 2.99M$ -1.09M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 137.18M$ 150.28M$ 174.51M$ 194.11M$ 180.86M
Total Assets$ 159.22M$ 184.69M$ 201.79M$ 221.17M$ 209.19M
Total Debt$ 11.75M$ 12.87M$ 13.97M$ 10.60M$ 11.75M
Net Debt$ -125.44M$ -137.41M$ -160.53M$ -183.51M$ -169.11M
Total Liabilities$ 190.45M$ 216.37M$ 249.24M$ 272.40M$ 294.21M
Stockholders Equity$ -31.23M$ -31.68M$ -47.45M$ -51.24M$ -85.03M
Cash Flow-
Free Cash Flow$ -19.64M$ -26.16M$ -22.23M$ -18.25M$ -25.70M
Operating Cash Flow$ -19.55M$ -26.05M$ -21.96M$ -18.24M$ -25.18M
Investing Cash Flow$ 21.51M$ 44.88M$ 12.87M$ -42.94M$ 26.04M
Financing Cash Flow$ 5.10M$ 174.00K$ 244.00K$ 29.67M$ 317.00K
Currency in USD

CytomX Therapeutics Earnings and Revenue History

CytomX Therapeutics Debt to Assets

CytomX Therapeutics Cash Flow

CytomX Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis